文献速递胃肠动力与功能性疾病

利那洛肽缩短便秘型肠易激综合征症状的应答时间:4项随机对照试验分析

Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials.
PubMed 文献 · Am J Gastroenterol · 2022-10-12

该研究汇总4项随机对照试验的事后分析,纳入2350例便秘型肠易激综合征患者(安慰剂1172例,利那洛肽290μg 1178例),采用Kaplan-Meier法分析腹部症状和完全自发排便的应答时间。结果显示超过50%的患者在3-4周(中位数)内腹部疼痛、不适或腹胀减轻≥30%,达到≥3次完全自发排便的中位时间为4周,部分患者应答延迟至4-12周。

要点

  • 超过50%的便秘型肠易激综合征患者在利那洛肽治疗3-4周(中位数)内腹部疼痛、不适或腹胀减轻≥30%。
  • 达到≥3次完全自发排便的中位时间为4周。
  • 4-12周延迟应答:腹痛约1/6患者,完全自发排便频率约1/10患者。

核心结论

  • 超过50%的便秘型肠易激综合征患者在利那洛肽治疗开始后4周内出现治疗应答。
  • 单个腹部症状和/或完全自发排便频率的获益仍可能在4-12周之间出现。
  • 一个症状无改善并不否定其他症状应答的可能性,强调与患者讨论所有症状、不应在4周时假定治疗无效。

研究设计与样本

  • 4项随机对照试验的事后汇总分析,纳入2350例患者(安慰剂1172例,利那洛肽290μg 1178例)。
  • 采用Kaplan-Meier法分析腹部症状(疼痛、不适、腹胀)和完全自发排便的应答时间,将患者分为早期应答(≤4周)、延迟应答(>4-12周)和无应答。

主要发现

  • 超过50%的便秘型肠易激综合征患者在利那洛肽治疗3-4周(中位数)内腹部疼痛、不适或腹胀减轻≥30%。
  • 达到≥3次完全自发排便的中位时间为4周。
  • 4-12周延迟应答:腹痛约1/6患者,完全自发排便频率约1/10患者。
  • 早期应答者比较显示,女性、白人、基线腹部症状较轻的患者更可能早期应答。

临床怎么用

  • 作者认为,一个症状无改善并不否定其他症状应答的可能性,强调与患者讨论所有症状、不应在4周时假定治疗无效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: These post hoc analyses provide clinically relevant data concerning time to response for individual irritable bowel syndrome with constipation (IBS-C) symptoms after linaclotide use. METHODS: Time-to-response data were pooled from 4 randomized controlled trials. Response time for abdominal symptoms (pain, discomfort, and bloating) and complete spontaneous bowel movements (CSBMs) were analyzed using the Kaplan-Meier method; patients were categorized as early responders (≤4 weeks), late responders (>4-12 weeks), or nonresponders. RESULTS: Among 2,350 patients (1,172 placebo and 1,178 linaclotide 290 μg), >50% of patients with IBS-C who initiated linaclotide treatment experienced a decrease of ≥30% in abdominal pain, discomfort, or bloating within 3-4 weeks (median). The median time to achieving ≥3 CSBMs was 4 weeks. Although not all linaclotide-treated patients responded within 12 weeks, a late response occurred between 4 and 12 weeks in 1 in 6 patients for abdominal pain and in approximately 1 in 10 patients for CSBM frequency. Comparisons of early responders, late responders, and nonresponders for both response definitions indicated that women, Whites, and patients with less severe baseline abdominal symptoms were more likely to respond early. DISCUSSION: Although treatment responses with linaclotide occurred in >50% of patients with IBS-C within 4 weeks of treatment initiation, benefits for individual abdominal symptoms and/or CSBM frequency can still occur between 4 and 12 weeks. A lack of improvement in one symptom does not negate the possibility of response for others, highlighting the importance of discussing all symptoms with patients and not assuming treatment futility at 4 weeks.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Brenner DM, Lacy BE, Ford AC, et al. Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials. Am J Gastroenterol. 2022. PMID: 36227782. doi:10.14309/ajg.0000000000002064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。